secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001867096-25-000100
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris unveils long-range strategy; targets ~$750M revenue by 2030
-----------------------------------------------------------------

- Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.
- Expects total revenue of ~$750M by 2030, led by Recorlev growth.
- Anticipates Recorlev annual net revenue of ~$1B in 2035; XP-8121 peak net revenue $1-3B.
- Cites Recorlev revenue acceleration as inflection point to self-fund near- and long-term growth.
- Hosts first Analyst and Investor Day on June 3, 2025, in New York City.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000100/0001867096-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000100/xers-20250603.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer